Menu Search
Equities

OSE Immunotherapeutics SA

6OP:FRA

OSE Immunotherapeutics SA

Actions
  • Price (EUR)10.02
  • Today's Change0.12 / 1.21%
  • Shares traded100.00
  • 1 Year change+130.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 15:53 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year OSE Immunotherapeutics SA's revenues fell -87.83% from 18.30m to 2.23m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 17.76m to a larger loss of 23.00m.
Gross margin--
Net profit margin55.17%
Operating margin64.52%
Return on assets41.60%
Return on equity88.54%
Return on investment49.66%
More ▼

Cash flow in EURView more

In 2023, cash reserves at OSE Immunotherapeutics SA fell by 6.95m. Cash Flow from Financing totalled 13.32m or 598.29% of revenues. In addition the company used 19.77m for operations while cash used for investing totalled 507.00k.
Cash flow per share2.43
Price/Cash flow per share4.37
Book value per share3.74
Tangible book value per share1.67
More ▼

Balance sheet in EURView more

OSE Immunotherapeutics SA has a Debt to Total Capital ratio of 35.02%, a lower figure than the previous year's 166.31%.
Current ratio4.93
Quick ratio--
Total debt/total equity0.5388
Total debt/total capital0.3502
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.